Diabetes Boosts CKD Patients' Comorbidities
PHILADELPHIA—Patients with chronic kidney disease (CKD) who also have diabetes have significantly higher rates of anemia, cardiovascular disease, and other comorbidities compared with nondiabetic CKD patients, study findings presented at Kidney Week 2011 show.
The study, by researchers at Eli Lilly and Company of Indianapolis, Ind., examined data from 116,512 CKD patients, of whom 45% had diabetes. A significantly higher proportion of diabetic CKD patients than nondiabetic CKD patients had anemia (46% vs. 35%), cardiometabolic risk factors (100% vs. 71%), cardiovascular disease (39% vs. 25%), nephritis and nephrosis (34% vs. 27%), other renovascular diseases (27% vs. 22%), cerebrovascular disease (17% vs. 12%), and disorders of fluid electrolyte and acid-base balance (20% vs. 14%).
The investigators, led by Justo Sierra-Johnson, MD, PhD, also noted that these rates rose as CKD stage increased. Diabetic CKD patients also had significantly higher rates of medication use for hypertension, lipid disorders, and anemia and incurred higher overall total medical and drug costs.
The researchers concluded that CKD patients with diabetes are a particularly high-risk group for associated comorbidities that require extensive medical resources.